SavedAdd your journal

Journals / Turkish Journal of Biology / 2020 / Cilt: 44 - Sayı: SI-1

An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19

Murat TOPUZOGULLARİ
Tayfun ACAR
Pelin PELİT ARAYICI
Burcu UÇAR
Erennur UĞUREL
Emrah Şefik ABAMOR
Tülin ARASOĞLU
Dilek BALIK-TURGUT
Serap DERMAN
Pages
215–227
Publication Date
2020-06-21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We have not only compared the peptide vaccine with other types of vaccines but also presented comprehensive literature information about development steps for an effective and protective formulation to give an insight into on-going peptide vaccine studies against SARS-CoV-2.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:SARS-CoV-2 is a new member of the coronavirus family and caused the pandemic of coronavirus disease 2019 (COVID-19) in 2020.
📊
Key Findings & Data:In this review, vaccine studies against COVID-19 have been summarized and detailed information about the epitope-based peptide vaccines against COVID-19 has been provided.
💡
Conclusion & Impact:We have not only compared the peptide vaccine with other types of vaccines but also presented comprehensive literature information about development steps for an effective and protective formulation to give an insight into on-going peptide vaccine studies against SARS-CoV-2.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:SARS-CoV-2 · COVID-19 · epitope-based peptide vaccine design

Abstract

SARS-CoV-2 is a new member of the coronavirus family and caused the pandemic of coronavirus disease 2019 (COVID-19) in 2020. It is crucial to design and produce an effective vaccine for the prevention of rapid transmission and possible deaths wcaused by the disease. Although intensive work and research are being carried out all over the world to develop a vaccine, an effective and approved formulation that can prevent the infection and limit the outbreak has not been announced yet. Among all types of vaccines, epitope-based peptide vaccines outshine with their low-cost production, easy modification in the structure, and safety. In this review, vaccine studies against COVID-19 have been summarized and detailed information about the epitope-based peptide vaccines against COVID-19 has been provided. We have not only compared the peptide vaccine with other types of vaccines but also presented comprehensive literature information about development steps for an effective and protective formulation to give an insight into on-going peptide vaccine studies against SARS-CoV-2.

🔖

Cite This Article

TOPUZOGULLARİ, M., ACAR, T., ARAYICI, P. P., UÇAR, B., UĞUREL, E., ABAMOR, E. Ş., ARASOĞLU, T., BALIK-TURGUT, D., DERMAN, S. (2020). An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19. Turkish Journal of Biology, Cilt: 44 - Sayı: SI-1, 215–227. https://ajindex.com/articles/204387

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Abdelmageed M. I., 2020,
  2. DESIGN MULTIEPITOPE, DOI [10.1101/2020.02.04.934232, DOI 10.1101/2020.02.04.934232] Acar T, 2019, INT J PEPT RES THER, V25, P911, DOI 10.1007/s10989-018-9739-0 Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254 Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w Almofti YA., 2018, AMERJ MICROBIOL RES, V6, P94 Amanat F, 2020,
  3. IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007 [Anonymous], 2020, USINEWS 04 US IN EU. Bahrami AA, 2019, INT REV IMMUNOL, V38, P307, DOI 10.1080/08830185.2019.1657426 Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698 Behrendt R, 2016, J PEPT SCI, V22, P4, DOI 10.1002/psc.2836 Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736 Bojin F., 2020, DESIGN EPITOPE BASED. Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1 Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361 Callaway E, 2020,
  4. NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y CAO XR, 2020, LUMINESCENCE 0115, DOI DOI 10.1126/SCIENCE.ABC1932 Cascella M., 2020, FEATURES EVALUATION. Chan W, 1999, FMOC SOLID PHASE PEP. Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6 Cho H, 2018, HUM VACC IMMUNOTHER, V14, P304, DOI 10.1080/21645515.2017.1389362 Enjuanes L., 1995, Corona- and related viruses: current concepts in molecular biology and pathogenesis Laval, Quebec, Canada 27 August-1 September 1994., P197 Fast E, 2020,
  5. POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484] Feng Y., 2020,
  6. BIORXIV, DOI DOI 10.1101/2020.03.03.962332 Glenny AT, 1926, J PATHOL BACTERIOL, V29, P31, DOI 10.1002/path.1700290106 Grifoni A, 2020,
  7. CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015 Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002 Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0 Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681 Huang CL, 2020,
  8. LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5 Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI [10.12688/f1000research.22507.2, 10.12688/f1000research.22507.1] Jensen KJ, 2013, METHODS MOL BIOL, V1047, P1, DOI 10.1007/978-1-62703-544-6 Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346 Joshi Amit, 2020, Inform Med Unlocked, V19, P100338, DOI 10.1016/j.imu.2020.100338 Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.mi